Printer Friendly

ANDRX SUBSIDIARY RECEIVES APPROVAL FOR TWO PATENTS

 FORT LAUDERDALE, Fla., June 23, 1993 /PRNewswire/ -- Andrx Corporation, a pharmaceutical holding company, announced today that its wholly owned subsidiary AndaSR Pharmaceuticals, Inc. received Notices of Allowance for two patents covering the use of Pelletized Pulsatile Delivery Systems (PPDS). The PPDS, developed by Chih-Ming Chen, Ph.D., president of AndaSR, delivers a specific quantity of drug at different and defined lag times which can be controlled to fit the kinetic characteristics of each drug. This versatile technology can be used to produce generic versions of various once-daily sustained release drugs such as Cardizem CD (NYSE: MKC) and Procardia XL (NYSE: PFE). In addition, the PPDS may be utilized to increase the bioavailability of specific drugs. This can result in products which require less drug to produce the same therapeutic effect as those currently being sold. Consequently, the product may be cheaper to produce, may result in decreased side effects and better patient compliance.
 Elliot F. Hahn, Ph.D. stated, "We are very pleased by the rapid approval of our applications by the United States Patent and Trademark Office. We believe that the PPDS provides Andrx with a unique drug delivery technology and gives us a strong foundation to develop and manufacture generic and brand name pharmaceutical products."
 Andrx is a pharmaceutical holding company consisting of three operating divisions: Anda Generics, a generic distribution company, AndaSR Pharmaceuticals, a developer and manufacturer of controlled- release generic products and Aura Labs, an ethical pharmaceutical company.
 -0- 6/23/93
 /CONTACT: Elliot F. Hahn, Ph.D., president of Andrx Corp., 305-584-0300, or fax 305-587-0395/


CO: Andrx Corporation ST: Florida IN: MTC SU:

RC-SS -- FL001 -- 4869 06/23/93 08:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 23, 1993
Words:277
Previous Article:ADVANCE CAPITAL MANAGEMENT REACHES 2ND MAJOR MILESTONE IN LAST 2 MONTHS
Next Article:JACOBS FAMILY FOUNDATION ANNOUNCES FOURTH GRANT IN PASADENA INITIATIVE
Topics:


Related Articles
C O R R E C T I O N -- Andrx Forms Chinese Subsidiary
C O R R E C T I O N -- Andrx Forms Chinese Subsidiary
ANDRX ALLOWED PATENTS FOR THREE DRUG DELIVERY SYSTEMS
ANDRX RECEIVES TWO PATENTS FOR DELIVERY SYSTEMS
ANDRX ANNOUNCES ADDITIONAL EQUITY INVESTMENT BY WATSON PHARMACEUTICALS
Andrx Enters into Agreement with HMR Concerning Its Generic Version Of Cardizem(R) CD
FDA Grants Final Approval Of Andrx's ANDA For Cardizem(R) CD
FDA Approves ANCIRC ANDA For Trental(R)
Hoechst Marion Roussel Announces Settlement In Cardizem(R) CD Patent Infringement Suit.
Synopsis of Andrx Corporation Presentation at Ryan, Beck & Company Southeast Research Group 8th Annual Institutional Conference.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters